SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to heightened speculation surrounding a potential buyout or major partnership, as investors track ongoing M&A activity in the weight-loss drug sector and analyze the competitive potential of VK2735 against industry leaders. The community is actively discussing the company's clinical trial progress and the perceived undervaluation of its obesity pipeline, with many members dismissing recent share price volatility as market noise in anticipation of upcoming data readouts.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is facing downward pressure following the company's decision to restrict investor withdrawals from a key private credit fund and the subsequent unloading of over a billion dollars in loan assets. While management frames the shift as a move to accelerate capital returns, the community is actively debating whether this signals a broader liquidity crunch within the private credit sector or represents a manageable adjustment to fund operations.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors digest the FDA approval of Foundayo, the company's first oral GLP-1 weight-loss pill, which significantly intensifies the competitive landscape against Novo Nordisk. Community discussion is heavily focused on the clinical efficacy and side-effect profile of Foundayo versus oral Wegovy, while broader sentiment remains polarized between enthusiasm for Lilly's commercial execution and concerns regarding supply chain hurdles and intensifying pricing competition.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is currently trending as a defensive heavyweight, with investors monitoring the company's strong clinical pipeline, including positive oncology data for multiple myeloma, while legal teams remain focused on ongoing talc-related litigation. The community is actively discussing JNJ's role as a reliable dividend compounder and evaluating the potential impact of long-term healthcare demand versus structural legal liabilities.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending as investors closely watch upcoming earnings and scrutinize the new leadership's ability to manage high debt levels while balancing subscriber growth against competitive market pressures. The community remains divided, with some betting on a defensive dividend play and share buybacks, while others express frustration over persistent service quality issues and skepticism toward the company's long-term growth narrative.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is trending as energy markets grapple with acute supply volatility and geopolitical instability centered on the Strait of Hormuz. Investors are actively debating whether current supply-side constraints and record-high commodity prices will sustain long-term sector gains or trigger broader economic demand destruction.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased social and trading activity driven by news of its quantum-resistant technology being cited by Google researchers, alongside anticipation for US regulatory clarity. The community remains divided between long-term holders optimistic about its institutional utility and active traders debating the impact of ongoing market volatility.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

The United States Natural Gas Fund is facing significant volatility as traders react to shifting weather forecasts and intense market pressure following a sharp sell-off. Community sentiment remains deeply divided, with many market participants actively debating the impact of seasonal demand transitions and the risks of holding highly leveraged products.

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB, Display and Component Inspection. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded on July 9, 1975 and is headquartered in Milpitas, CA.

KLA Corp.

KLA Corp. is currently trending as investors weigh strong capital return initiatives, including aggressive share buybacks, against ongoing concerns regarding semiconductor sector volatility and geopolitical supply chain risks. The community remains closely divided between the bull case, centered on KLA's essential role in advanced process control for the AI roadmap, and the bear case, driven by macro uncertainty and equipment delivery headwinds.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing heightened community interest as investors debate the potential for a strategic acquisition, with many pointing to the company's significant cash position and active boardroom discussions. While some traders are focused on technical indicators and speculative M&A targets like SNAP, others are expressing frustration over the lack of immediate corporate catalysts and are pushing for clarity on the CEO's compensation and future growth strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The weakness in revenue was led by the Services segment, which declined 9% due to weakness in construction revenue.</li><li>The company’s net income from continuing operations attributable to company stockholders totaled $1.16 per diluted share, compared to $1.12 per diluted share in 2024.</li><li>Retail revenue jumped year over year, driven by an 8.3% increase in water volume sold, to a record 1.09 billion gallons.</li></ul>Consolidated Water (CWCO) stock fell 16% during extended hours of trading on Monday after its fourth-quarter (Q4) results disappointed investors.&nbsp;The company reported a 1% decline in total revenue to $132.1 million in FY 2025, well short of analysts’ estimates of $137.9 million, as per data from&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://fiscal.ai">Fiscal.ai</a>. The weakness in revenue was led by the Services segment, which declined 9% to $46.3 million, primarily due to weakness in construction revenue.“Our retail, bulk and manufacturing revenues and operating incomes in 2025 were consistent with our expectations,” commented Consolidated Water CEO, Rick McTaggart.&nbsp;“However, our services revenue from continuing operations did not meet our expectations due to a permitting delay related to our 1.7 million gallon per day seawater desalination plant project in Kalaeloa, Hawaii. We believe that this type of delay is common for the complex, multi-agency permitting process required for a project of this scale and is not due to any failures on the part of Consolidated Water,” McTaggart added.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>The company’s net income from continuing operations totaled $18.6 million, or $1.16 per diluted share, compared to $17.9 million, or $1.12 per diluted share, in 2024.Retail revenue jumped year over year to a record 1.09 billion gallons, driven by an 8.3% increase in water volume sold. This increase resulted from significantly lower rainfall on Grand Cayman and a 6.6% increase in the number of customer accounts in the company’s license area, the company said.&nbsp;“The continued strength of the Cayman Islands economy and historically low rainfall in our exclusive utility service area on Grand Cayman resulted in our retail segment revenue increasing about 6% compared to the previous year,” McTaggart further said.&nbsp;<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around CWCO stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen 14% year to date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail sentiment around CWCO stock trended in ‘bullish’ territory amid ‘extremely high’ message volume. 

CWCO Stock Dives 16% After-Hours On FY25 Revenue Miss

The company reported a decline of 1% in its total revenue of $132.1 million in FY 25.

Equity

The company reported a decline of 1% in its total revenue of $132.1 million in FY 25.


<ul class="summary-bullets"><li>Esperion highlighted future growth plans, including expanding U.S. market penetration and advancing its oral triple-combination program.</li><li>The company said that its acquisition of Corstasis Therapeutics also advances its Vision 2040 strategy.</li><li>Esperion also added that it plans to expand geographically through continued collaboration with its global partners.</li></ul>Esperion Therapeutics Inc. (ESPR) shares fell more than 6% in Tuesday morning’s trade after the company reported a mixed fourth quarter.Esperion reported earnings per share (EPS) of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million, according to Fiscal.ai data.“2025 was a defining year for Esperion. We delivered strong growth in our U.S. cardiovascular franchise, broadened access and adoption among statin-intolerant or statin-resistant patients, and strengthened the durability of our business with important intellectual property and market access advances,” said Esperion CEO Sheldon Koenig.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ESPR">Esperion</a> trended in the ‘extremely bullish’ territory despite the mixed fourth-quarter (Q4) performance. Message volumes were at ‘extremely high’ levels at the time of writing.One bullish user stated that the ESPR stock appears way undervalued.<stembedurl>https://stocktwits.com/DP000/message/647094104</stembedurl>Another user stated that Esperion has massive catalysts coming up.<stembedurl>https://stocktwits.com/BRLondon/message/647092901</stembedurl><h2 class="st-heading-2">Esperion Highlights Upcoming Catalysts</h2>Esperion stated that it is investing in several clear catalysts for future growth. These include deeper penetration in the U.S. market supported by strong payer coverage, as well as progress on its oral triple-combination program designed to compete with products currently on the market or in development.The firm also added that it plans to expand geographically through continued collaboration with its global partners.“We are entering 2026 with confidence, discipline, and a long-term mindset focused on creating lasting value for patients, providers, and shareholders,” Koenig added.The company said that it aims to pursue new therapeutic opportunities and develop next-generation inhibitors targeting multiple life-threatening diseases.ACLY is a metabolic enzyme involved in breaking down nutrients and producing cholesterol and fatty acids, making it a potential target for treating a range of diseases.<h2 class="st-heading-2">Koenig Says Corstasis Deal Advances Vision 2040</h2>During a post-earnings call with analysts, Koenig said that the planned acquisition of Cortasis Therapeutics advances the company’s Vision 2040.“The acquisition of Corstasis is a catalyst for additional long-term value and a testament to our commitment to building a larger and sustainably profitable company. Our priority is to grow these two franchises to their multi-billion-dollar potential,” he said.Esperion announced earlier this month that it had entered into an agreement to acquire Corstasis for an upfront payment of $75 million. Corstasis shareholders will also be eligible to receive an additional $180 million upon the attainment of certain regulatory and commercial milestones, as well as royalties on sales of Enbumyst and follow-on products.<a href="https://stocktwits.com/symbol/ESPR">ESPR stock</a> is down 21% year-to-date, but up more than 84% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-hims-deal-turns-wall-street-bullish-hims-stock-upgrades/cZdos7IRI7d">Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Esperion Therapeutics Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts

Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million.

<ul class="summary-bullets"><li>For Q4, Arq reported total revenue of $29.4 million, reflecting an increase of 9%.</li><li>Arq said it has decided to pause GAC production to conduct a comprehensive engineering and production process optimization review.</li><li>The company said that Jay Voncannon will no longer serve as the Company’s Chief Financial Officer, effective immediately.</li></ul>Arq stock plunged 22% during extended hours of trading on Monday after it reported a larger fourth-quarter 2025 loss compared to the year-ago quarter.The company reported a net loss of $52.6 million in FY 2025, versus a net loss of $5.1 million in FY 2024. In Q4 2025, net loss came at $50.0 million, compared to a net loss of $1.3 million in Q4 2024.&nbsp;<h2 class="st-heading-2">Earnings</h2>Arq reported revenue totaling $29.4 million for the fourth quarter of 2025, reflecting an increase of 9% compared to $27.0 million in the prior year period. The increase was driven predominantly by enhanced volumes and pricing.Arq’s gross margin reduced to 13.6% for the fourth quarter of 2025, compared to 36.3% in the prior year period. The reduction in gross margin was driven by higher costs associated with GAC start-up.<h2 class="st-heading-2">GAC Strategy Updates</h2>Arq said it has decided to pause GAC production to conduct a comprehensive engineering and production process optimization review of the path forward for the company’s Granular Activated Carbon (GAC) for water, air, and industrial purification business.This decision comes after independent tests in late January 2026 revealed that the Arq’s existing thermal oxidizer can support only about 15 million pounds of GAC production per year and would need further modifications to reach the initial goal of 25 million pounds or more annually.In bid to transition away from using Corbin Wetcake for its GAC products, Arq is temporarily idling its Corbin facility and in connection recorded a non-cash impairment charge of $45 million in Q4 2025.<h2 class="st-heading-2">CFO Change</h2>The company said that Jay Voncannon will no longer serve as the company’s Chief Financial Officer, effective immediately.Stacia Hansen will serve as the company’s principal financial officer while continuing in her role as Chief Accounting Officer.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around ARQ trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen 29.3% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Arq stock plunged 22% during extended hours of trading on Monday after it reported a larger fourth-quarter 2025 loss compared to the year-ago quarter.

Why Is ARQ Stock Plummeting?

The company reported Q4 2025 net loss of $50.0 million vs. net loss of $1.3 million in Q4 2024. 

<ul class="summary-bullets"><li>Rumble CEO said that the firm has reached an inflection point.</li><li>The company said its loss per share during the quarter was at $0.13, compared to $1.15 per share from the year-ago quarter.</li><li>The loss during the quarter marginally missed analyst estimates of loss of $0.1 per share.</li></ul>Rumble Inc.&nbsp;shares fell nearly 4% in extended hours of trading on Thursday after it reported a 10% decline in fourth-quarter (Q4) revenue compared to the year-ago quarter.&nbsp;Revenue for Q4 was $27.1 million, in line with analyst expectations, as per Fiscal.ai. The revenue was a decrease of 10% from $30.2 million reported in the second quarter of 2024.&nbsp;The decline was attributable to a decrease in Audience Monetization revenues and lower Other Initiatives revenues, the company said.&nbsp;"Rumble has reached an inflection point. The investments we made throughout 2025, in platform stability, creator monetization, short-form video, and our sales infrastructure, are beginning to bear fruit,” said Chris Pavlovski, Rumble's Chairman and CEO.&nbsp;&nbsp;<h2 class="st-heading-2">Results In Detail</h2>Net loss for the fourth quarter was $32.7 million compared to a loss of $236.8 million in the fourth quarter of 2024, principally attributable to a $184.7 million loss in the change in fair value of derivative expense related to Tether's strategic investment in Rumble.The company said its loss per share during the quarter was at $0.13, compared to&nbsp;a loss of&nbsp;$1.15 per share from the year-ago quarter. The loss during the quarter marginally missed analyst estimates of loss of $0.1 per share.The company said that during the fourth quarter, it secured a $100 million advertising commitment from Tether, structured as $50 million per year over two years beginning in Q1 2026. The efforts are designed to advance Rumble Wallet integration, expand creator monetization, and accelerate new advertising solutions on the platform.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around RUM stock trended in&nbsp;the ‘bullish’ territory amid ‘high’ message volume.&nbsp;One bullish user predicted that Rumble’s 2026 looks good.&nbsp;<stembedurl>https://stocktwits.com/FredettenWahoo/message/646743733</stembedurl>Another user said that they knew the results will be in line with estimates as the company has declared results early.&nbsp;<stembedurl>https://stocktwits.com/Prostar/message/646743582</stembedurl>Shares in the company have fallen 13.4% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, a person holds a smartphone displaying the logo of Rumble Inc. 

Rumble Stock Is Diving After Hours – What Happened To Q4 Revenue?

The decline in Q4 revenue was attributable to a decrease in Audience Monetization revenues and lower Other Initiatives revenues. The revenue was in line with analyst expectations, per Fiscal.ai. 

<ul class="summary-bullets"><li>The company saw payment volumes go up by 10% year-over-year to $43.9 billion during the quarter.&nbsp;</li><li>BTIG analyst Andrew Harte said&nbsp;the firm&nbsp;sees&nbsp;an upside in PSFE shares over the next year from leverage reduction.&nbsp;</li><li>BTIG kept a ‘Buy’ rating on the shares.&nbsp;</li></ul>Paysafe stock rallied 22% on Tuesday after it reported&nbsp;an increase&nbsp;in quarterly revenues, prompting financial services firm BTIG to see an uptick in the company's shares over the next year.&nbsp;The company posted&nbsp;a 4% rise&nbsp;in Q4 revenue of $438.4 million,&nbsp;amid an uptick in payment volume, compared to $420.1 million from the year-ago period.<h2 class="st-heading-2">Q4 Snapshot</h2>The company saw payment volumes go up by 10% year-over-year to $43.9 billion during the quarter.&nbsp;Paysafe (PSFE) said that adjusted net income fell to $25.5 million or $0.46 per diluted share versus $29.5 million or $0.48 per share.&nbsp;"Paysafe’s fourth quarter results are consistent with what we outlined in November, and the full year of 2025 marks our third consecutive year of organic revenue growth,” said Bruce Lowthers, CEO of Paysafe.&nbsp;<h2 class="st-heading-2">Outlook For 2026</h2>The company said it sees 2026 revenue in the range of $1.79 billion&nbsp;to $1.83 billion, whose midpoint is in line with the consensus of $1.81 billion, as per data from&nbsp;Fiscal.ai. Paysafe sees 2026 adjusted EPS in the range of $2.12-$2.32. Analysts on average had expected profit of $2.29 per share.&nbsp;“In 2026, we are focused on creating outstanding experiences for both our customers and employees, while targeting higher revenue growth and double-digit adjusted earnings per share growth,” he added.&nbsp;<h2 class="st-heading-2">Analyst Take</h2>BTIG analyst Andrew Harte said&nbsp;the firm sees&nbsp;an upside in PSFE shares over the next year from leverage reduction.&nbsp;However, the analyst lowered the firm's price target on Paysafe to $10 from $11. BTIG kept a ‘Buy’ rating on the shares.&nbsp;The firm said the company's Q4 results were mixed as the Digital Wallet segment beat revenue expectations, while the Merchant Solutions segment missed. BTIG does not expect Paysafe to accelerate growth towards high-single-digit over the medium-term.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on <a href="https://stocktwits.com/symbol/PSFE">PSFE stock</a> trended in&nbsp;the ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen 63% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Paysafe sees 2026 revenue in the range of $1.79 billion to $1.83 billion, whose midpoint is in line with the consensus of $1.81 billion, as per data from Fiscal.ai.

Paysafe Rallies As BTIG Sees Upside In Stock Over The Next Year

The company posted Q4 revenue of $438.4 million compared to $420.1 million from the year-ago period. 

<ul class="summary-bullets"><li>The company's total revenue was helped by growth in network services whose revenue represented 19% year-over-year growth. Security revenue showed 32% year-over-year growth.&nbsp;</li><li>Fastly also swung to profit in the fourth quarter compared to the year-ago.</li><li>Fastly said it expects total revenue in the range of $168 million to $174 million for the first quarter of 2026. Analysts expected Q1 2026 revenue of $159.6 million, as per fiscal.ai.&nbsp;</li></ul>Fastly (<a href="https://stocktwits.com/symbol/FSLY">FSLY</a>) shares soared 25% in extended hours of trading on Wednesday after its record fourth-quarter revenue beat estimates.&nbsp;The rally in the stock turned investors bullish on the stock with predictions of the stock to rise 100% by the end of Feb.&nbsp;<a href="https://stocktwits.com/BullyingTheBearss/message/644734186">https://stocktwits.com/BullyingTheBearss/message/644734186</a>The company posted a fourth quarter revenue of $172.6 million that grew 23% year over year. Analysts on average expected revenue of $161.4 million as per data from fiscal.ai.&nbsp;"Our fourth quarter results mark an inflection in Fastly’s growth as we achieved record revenue, gross margin, and operating profit,” said Kip Compton, CEO of Fastly. “In 2025 we made significant progress on Fastly’s transformation and delivered great results.”<h2 class="st-heading-2">Q4 Snapshot</h2>The company's total revenue was helped by growth in network services whose revenue represented 19% year-over-year growth. Security revenue showed 32% year-over-year growth.&nbsp;The company also swung to profit in the fourth quarter compared to the year-ago. It reported adjusted net income per diluted share of $0.12, compared to adjusted net loss per diluted share of $0.02 in the fourth quarter of 2024.The company said it generated $22.4 million of operating cash flow compared to $5.2 million of operating cash flow in the fourth quarter of 2024.&nbsp;<h2 class="st-heading-2">Outlook</h2>Fastly said it expects total revenue in the range of $168 million to $174 million for the first quarter of 2026. Analysts expected Q1 2026 revenue of $159.6 million, as per fiscal.ai.&nbsp;It said its full year-revenue is expected to be in the range of $700 million to $720 million. The higher end of the FY2026 forecast shows 15% growth in full year revenue compared to $624 million it reported for FY2025.&nbsp;It also said it expects adjusted profit to be in the range of $0.07 per share to $0.10 per share for Q1 2026. Analysts on average expected adjusted profit to be $0.01 per share.&nbsp;“As we look toward 2026, we anticipate continued momentum, with AI as an increasing tailwind for our business,” Compton added.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around FSLY trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;One user, however, said that Fastly’s earnings did not impress them, except for free cash flow and profitability.&nbsp;<stembedurl>https://stocktwits.com/starwarsjunkie7/message/644734123</stembedurl>Shares in the company have risen 17% over the past year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/crypto-token-uni-rises-how-did-blackrock-drive-the-rally/cZb6jCHR4Ad">Crypto Token UNI Jumps 14% - How Did BlackRock Drive The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Employees work at Fastly's office in San Francisco on Friday, July 20, 2018. 

Why Is Retail Seeing 100% Jump In Fastly’s Stock By Month-End?

The company posted a fourth quarter revenue of $172.6 million that grew 23% year over year. Analysts on average expected revenue of $161.4 million as per data from fiscal.ai. 

<ul class="summary-bullets"><li>The FDA’s concerns were limited to packaging, labeling, and administration issues, the company said.</li><li>Aquestive has already modified the pouch design, updated instructions for use, and revised labelling.</li><li>The firm is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K last year.</li></ul>Shares of Aquestive Therapeutics (AQST) surged more than 35% on Monday morning, after receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.A CRL indicates that while a drug has not been approved in its current form, it allows the sponsor to address the issues raised by the FDA and seek re-approval.<h2 class="st-heading-2">FDA’s Concerns</h2>The FDA’s concerns were limited to packaging, labeling, and administration issues identified in a human factors validation study. The FDA noted that some users had difficulty opening the pouch and correctly placing the film, which could pose safety risks during emergency situations. The agency did not raise questions about the drug’s comparability data or manufacturing processes, the company said.To address the feedback, Aquestive has modified the pouch design, updated instructions for use, and revised labeling. The company plans to conduct a new human factors study alongside a single pharmacokinetics (PK) study requested by the FDA. No additional trials are required.Based on the initial review, Aquestive expects to resubmit the application as early as the third quarter of 2026 and will seek a rapid review.<h2 class="st-heading-2">Europe Update</h2>Aquestive is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K. in 2025. The European Medicines Agency indicated that no additional clinical trials are required, with submissions in Europe and Canada expected in the second half of 2026. The company also anticipates feedback from the U.K.’s MHRA in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a session earlier, amid ‘high’ message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_c092cd62f6.webp" alt="AQST.jpg">One user brushed off concerns about the CRL, noting there were no key issues.<stembedurl>https://stocktwits.com/BigGainTom/message/643649716</stembedurl>While the stock has gained nearly 35% over the past year, its year-to-date losses are around 40%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/precious-metals-extend-historic-rout/cZbg8EJR4kf">Gold, Silver Continue To Decline – Analysts Warn Of Crowded Trades As Precious Metals Extend ‘Historic Rout’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did AQST Stock Jump 35% Today?

The company received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.

Should iShares Russell 2000 Value ETF (IWN) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Anaphylm is Aquestive’s sublingual epinephrine film for allergic reactions.</li><li>The Anaphylm application is supported by 11 clinical studies involving 411 subjects, the company said.</li><li>Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA date on January 31, it added.</li></ul>Shares of Aquestive Therapeutics (AQST) plunged 40% in pre-market trading on Friday after the company announced that it received a letter from the U.S. Food and Drug Administration (FDA) identifying deficiencies that currently prevent labeling discussions on Anaphylm.Anaphylm is Aquestive’s sublingual (under the tongue) epinephrine film for allergic reactions.However, the FDA also confirmed its review of the New Drug Application (NDA) remains ongoing, and no final decision has been made.Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA (Prescription Drug User Fee Act) date on January 31, noting that delays in receiving details could impact the approval timeline. A PDUFA date is the FDA's target date to make a decision on a drug application.The Anaphylm application is supported by 11 clinical studies involving 411 subjects, demonstrating pharmacokinetics comparable to epinephrine auto-injectors and a similar safety profile, Aquestive added.“As part of its ongoing review of the Company’s NDA for Anaphylm, the FDA notified us that it had identified deficiencies in the NDA that preclude discussion of labeling and post-marketing commitments at this time. Although the notification did not specify the deficiencies, Aquestive is working to understand and resolve the concerns. The FDA stated that the notification does not reflect a final decision on the pending application and the FDA’s review remains ongoing,” said Dan Barber, President and Chief Executive Officer of Aquestive.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the strong intraday decline, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/AQST">AQST</a> turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_2de986106b.webp" alt="AQST.jpg">Over the past year, the stock has gained 23%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Plug Power said it was impacted by the speed and development of hydrogen economy.

Why Did AQST Stock Plunge 40% In Pre-Market Today?

The company said the U.S. FDA identified deficiencies that prevent labeling discussions for a drug to treat allergic reactions.

AQST Stock Plunges On An FDA Setback For Its Allergy Drug – Here’s What Has Changed 

Should Vanguard S&P Small-Cap 600 Value ETF (VIOV) Be on Your Investing Radar?

iShares Trust - iShares Russell 2000 Value ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$192.19
Prev Close	$190.76
Open	$188.14
Dividend Yield	N/A
50-Day Moving Average	$194.16
Beta	N/A
Avg. Volume	789,781.65
PE Ratio	N/A

52-Week High	$203.01
52-Week Low	$129.38
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IWN
iShares Russell 2000 Value ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWN News

IWNiShares Russell 2000 Value ETF